Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

-vascular drugs have synergistic effects is worth studying. This study is a phase II prospective clinical study of PD-1 inhibitor combined with bevacizumab and FOLFIRI regimen in the second-line treatment

  • 0 views
  • 12 Sep, 2021
  • 1 location
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel

  • 12 views
  • 14 Nov, 2021
  • 448 locations
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) (BABST-C)

Bevacizumab, an antibody against vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens has been approved in the 1st and 2nd line treatments for metastatic colorectal cancers(mCRC). Other inhibitors of the VEGF pathway, such as Ramucirumab and Aflibercept are also approved in the 2nd line therapy. Apatinib is …

health screening
folfox regimen
capecitabine
liver metastasis
vegf
  • 0 views
  • 01 Feb, 2022
  • 1 location
Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.

metastatic pancreatic ductal adenocarcinoma
irinotecan
modified folfirinox regimen
diabetes
induction chemotherapy
  • 13 views
  • 26 Feb, 2022
  • 1 location
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept Irinotecan (Day 1 or Day 1 3) 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.

irinotecan
liver metastasis
platelet count
calcium
folfiri regimen
  • 0 views
  • 02 Sep, 2021
  • 1 location
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Bevacizumab, as an antibody of vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens for metastatic colorectal cancer, has become the classical first-line treatment. However, vast majority of patients eventually will suffer progression disease. The second-line treatment includes replacing chemotherapy regimens whistle continuing bevacizumab or other anti-VEGF antibodies, …

  • 0 views
  • 22 Jan, 2021
  • 1 location